Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, 831 Blockley, 423 Guardian Drive, Philadelphia, PA, 19104, USA.
Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Obes Surg. 2019 Mar;29(3):975-982. doi: 10.1007/s11695-018-3604-2.
Obesity is a major risk factor for end-stage kidney disease (ESKD) and is often a barrier to kidney transplantation. However, limited evidence exists evaluating postoperative bariatric surgery outcomes in patients with chronic kidney disease (CKD) and ESKD.
We performed a retrospective cohort study of patients who underwent bariatric surgery in 2015-2016 using the national Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program dataset. Propensity score matching was used to balance characteristics across patients with CKD and ESKD vs. those without CKD.
There were 323,034 patients without CKD, 1694 patients with CKD, and 925 patients with ESKD who underwent bariatric surgery. Patients with CKD and ESKD had a significantly increased risk of 30-day reoperation (CKD odds ratio [OR] 2.25 95% confidence interval [CI] 1.45-3.51; ESKD OR 3.10, 95% CI 1.72-5.61) and readmission (CKD OR 1.98, 95% CI 1.53-2.56; ESKD OR 2.97, 95% CI 2.05-4.31) compared to patients without CKD; mortality risk was elevated in patients with ESKD (OR 11.59, 95% CI 6.71-20.04) but not in those with CKD (OR 1.00, 95% CI 0.32-3.11). Rates of adverse outcomes were < 15% across all groups. There were 12, 50, and 172 deaths per 1000 person-years among patients without CKD, with CKD, and with ESKD, respectively.
Patients with CKD and ESKD experienced higher risk of postbariatric surgery complications compared to those without kidney disease, although absolute complication rates were low across all groups. CKD and ESKD should not be perceived as contraindications to bariatric surgery.
肥胖是终末期肾病(ESKD)的一个主要危险因素,且往往是肾移植的障碍。然而,目前评估慢性肾脏病(CKD)和 ESKD 患者术后减重手术结果的证据有限。
我们使用全国代谢和减重手术认证和质量改进计划数据集,对 2015-2016 年接受减重手术的患者进行了回顾性队列研究。使用倾向评分匹配来平衡 CKD 和 ESKD 患者与无 CKD 患者的特征。
共有 323034 例无 CKD 患者、1694 例 CKD 患者和 925 例 ESKD 患者接受了减重手术。CKD 和 ESKD 患者 30 天再次手术的风险显著增加(CKD 比值比[OR]2.25,95%置信区间[CI]1.45-3.51;ESKD OR 3.10,95% CI 1.72-5.61)和再入院(CKD OR 1.98,95% CI 1.53-2.56;ESKD OR 2.97,95% CI 2.05-4.31),而无 CKD 患者的风险则较低;与无 CKD 患者相比,ESKD 患者的死亡率升高(OR 11.59,95% CI 6.71-20.04),但 CKD 患者的死亡率没有升高(OR 1.00,95% CI 0.32-3.11)。所有组的不良结局发生率均<15%。无 CKD、CKD 和 ESKD 患者的每 1000 人年分别有 12、50 和 172 人死亡。
与无肾脏疾病的患者相比,CKD 和 ESKD 患者在接受减重手术后并发症的风险更高,尽管所有组的并发症发生率均较低。CKD 和 ESKD 不应被视为减重手术的禁忌证。